Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations
Dual inhibition of the angiopoietin (Ang)/Tie and vascular endothelial growth factor (VEGF) signalling pathways in patients with retinal diseases, such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME), may induce greater vascular stability and contribute to in...
Saved in:
Main Authors: | Sanjay Sharma, David T Wong, Shaheer Aboobaker, David Maberley, Pradeepa Yoganathan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | BMJ Open Ophthalmology |
Online Access: | https://bmjophth.bmj.com/content/10/1/e001967.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections
by: P. ET. Lau, et al.
Published: (2018-01-01) -
Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
by: Filipe Mira, et al.
Published: (2017-01-01) -
Anti-VEGF in a Marathon Runner’s Retinopathy Case
by: Alexander Kahjun Soon, et al.
Published: (2016-01-01) -
Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practice
by: E.A. Abdulaeva, et al.
Published: (2020-06-01) -
Human Factors Studies to Assess the Usability of the Faricimab Prefilled Syringe
by: Barakat MR, et al.
Published: (2025-02-01)